How Did the Man With Cancer Begin to Heal with mRNA Vaccines?

He felt like he was reborn with the cancer vaccine he tried as “Last Hope” Adrian Taylor, is responding to treatment and one of his tumors has shrunk. Taylor was also one of the first people to benefit from cancer vaccines in England. there was hope.

In addition to Adrian Taylor’s treatment process personalized cancer vaccines You can examine the treatment process in this article, perhaps you can inform one of the cancer patients around you and open a new door for the treatment process.

Adrian Taylor had only one hope. And that was to participate in a new clinical trial.

Adrian Taylor in 2021 to head and neck cancer caught. After receiving chemotherapy and radiotherapy, he had a PET/CT done in 2022. The good news was that the cancer in his neck and head was about to disappear. incurable He learned that he was qualified.

Learning that there was a 100% chance of dying without treatment, Taylor met with his doctor, thinking that he had to survive for his 4 children and wife. Taylor realized that one of the tumors had grown from 9 mm to 25 mm in a short time and was not suitable for surgery. experimental treatments He started researching.

Personalized cancer vaccine Taylor, who presented and was deemed fit for experimental treatment, took another dose every three weeks after receiving her first dose and underwent screening every eight weeks. The results of the last scan were very promising for both the doctor and Taylor. Taylor’s largest tumor, which was 25 mm, shrank to 4.6 mm.

Taylor also stated in her interviews that she was very happy for the moments when she could do many things that she thought she could not do. Taylor, treatment limited to two years During the process, he will continue to receive the vaccine regularly.

What is a personalized cancer vaccine?

that will revolutionize cancer mRNA, the same approach used in COVID-19 vaccines. mRNA has actually been around for nearly 10 years. cancer treatment tested for. Its success in COVID-19 was promising for scientists.

mRNA is a protein that instructs cells to make proteins. genetic planning. First of all, the proteins that cause tumor growth genetic mutations being analysed. The molecule, also called the neoantigen, which gives instructions for the tumor protein, is then produced in the cells.

After the molecules produced are injected into the patient, the patient is instructed to produce proteins that will cause an immune response against the proteins present in the tumor cells. Dendritic cells, which are immune cells that can be called the sentinels of the immune system, turn the vaccine and release the antigens to the cells. initiates the immune response.

Studies continue according to cancer types.

Many clinical studies colorectal and pancreatic cancer continues to test the mRNA vaccine against various types of cancer, such as These vaccines are not evaluated alone but in combination with other immune-boosting drugs.

Prostate and skin cancer Six cancer vaccines are being trialled in Clatterbridge alone, including Experts say that by 2030, personalized vaccines should be made for 10,000 patients.

mRNA is more than a vaccine.

James Spicer, Professor of Experimental Cancer Medicine at King’s College London, underlines that it is not enough to just call mRNA a vaccine. Spicer for mRNA “RNA therapeutics” says.

It seems possible that metastatic cells will remain behind after the tumor of patients who have undergone surgery for cancer is removed. Instead of waiting for it to metastasize, the genetic code taken from the tumor is sequenced and a vaccine is prepared against abnormal proteins. Thus, if the immune system recognizes this protein and encounters it again, learning to fight.

Promising results continue to be obtained.

Other results from personalized cancer vaccine trials are promising for the future of cancer. vaccinated high risk skin cancer Tests in more than three-quarters of its patients showed no relapse after 18 months.

One of the most aggressive types of cancer to pancreatic cancer Good news was also given in the studies on the subject. Half of the 16 pancreatic cancer patients undergoing the vaccine trial at the Memorial Sloan Kettering Cancer Center in New York no recurrence or this process is delayed.

We hope that vaccine studies will continue at full speed and become accessible to everyone.